Document is current
Any future updates will be listed below
-
Authors
Sheih, Alyssa
Voillet, Valentin https://orcid.org/0000-0002-5751-3881
Hanafi, Laïla-Aïcha
DeBerg, Hannah A.
Yajima, Masanao
Hawkins, Reed
Gersuk, Vivian https://orcid.org/0000-0003-4123-9926
Riddell, Stanley R.
Maloney, David G.
Wohlfahrt, Martin E. https://orcid.org/0000-0001-7342-6043
Pande, Dnyanada
Enstrom, Mark R. https://orcid.org/0000-0003-2635-3771
Kiem, Hans-Peter https://orcid.org/0000-0001-5949-4947
Adair, Jennifer E. https://orcid.org/0000-0003-4599-016X
Gottardo, Raphaël https://orcid.org/0000-0002-3867-0232
Linsley, Peter S.
Turtle, Cameron J.
-
Funding
Funding for this research was provided by:
Juno Therapeutics/Celgene Inc. Fred Hutchinson Immunotherapy Integrated Research Center Bezos Family
- License Information
-
More Information
Article History
Received: 22 April 2019
Accepted: 4 December 2019
First Online: 10 January 2020
Competing interests
: S.R.R. received research funding from Juno Therapeutics, a Celgene company, has patents licensed to Juno Therapeutics, a Celgene company, has equity ownership in Celgene, and has served on advisory boards for Adaptive Biotechnologies, Cell Medica, Juno Therapeutics, a Celgene company, and NOHLA. D.G.M. received research funding from GlaxoSmithKline and Juno Therapeutics, a Celgene company. H.P.K. is a consultant to and has ownership interests with Rocket Pharma and Homology Medicines, is a consultant to CSL Behring and Magenta Therapeutics, and is an inventor on patent applications (#62/351,761, #62/428,994, and #PCT/US2017/037967) submitted by the Fred Hutchinson Cancer Research Center that cover the selection and use of cell populations for research and therapeutic purposes, as well as strategies to assess and/or produce cell populations with predictive engraftment potential. C.J.T. received research funding from Juno Therapeutics, a Celgene company, and Nektar Therapeutics, has patents licensed to Juno Therapeutics, a Celgene company, has served on advisory boards, has equity ownership in Caribou Biosciences, Eureka Therapeutics, and Precision Biosciences, and has served on advisory boards for Aptevo, Juno Therapeutics, a Celgene company, Kite, a Gilead Company, Nektar Therapeutics, Novartis, Allogene, Myeloid Therapeutics, and PACT Pharma. R.G. has received consulting income from Juno Therapeutics, Takeda, Infotech Soft, Celgene, has received research support from Janssen Pharmaceuticals and Juno Therapeutics, and declares ownership in Cellspace Biosciences. The remaining authors declare no competing financial interests. Companies funding this research did not have any role in the study design or data analysis and interpretation.
